This article is more than 5 years old. Information may no longer be current.

LenSx receives FDA clearance for corneal flap creation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has cleared Alcon’s LenSx laser platform for creating corneal flaps in refractive surgical procedures, according to a press release.

The new functionality will become available in 2013, the release said. The laser platform already has FDA clearance for capsulotomy, lens fragmentation and all corneal incisions for cataract surgery.

“We are committed to continue to partner with surgeons to provide innovations for the LenSx laser to improve ophthalmic surgical procedures,” Stuart Raetzman, Alcon’s head of global commercial strategy, said in the release.

The new modality will enable surgeons to tailor treatment to meet the specific needs of patients requiring corneal refractive surgery, according to the release.

Since it was introduced in 2011, the LenSx has been used to perform more than 50,000 cataract surgeries in 42 countries, the release said.